Bridgepoint Development Capital Acquires Quotient Clinical

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-01-08-2014
Volume 10
Issue 1

Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry, has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum. Quotient Clinical has developed a platform that offers an integrated approach to formulation development, real-time drug product manufacturing, and clinical testing.

Quotient Clinical is currently part of Quotient Group, which is disposing of the business and represents a primary management buyout. The transaction is subject to standard regulatory clearances.

Source: Bridgepoint Development Capital

Articles in this issue
New Dynamics in Drug Pricing and Prescribing
Janssen Announces Drug Donation Program for HIV Treatment-Experienced Children
Miller_Jim-831890-1408528974207.jpg
Climate Change Drives New Opportunities in Outsourcing
Jimmy Carter and Pfizer Mark 15-Year Effort To Help End Blinding Trachoma
BMS Grants Support Mental Health Needs of US Military Veterans
Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million
Cambrex Completes FDA Inspection
Metrics Appoints New Vice-President
Bridgepoint Development Capital Acquires Quotient Clinical
GDUFA Off to Good Start, But Storm Clouds on the Horizon
Deficiencies Discovered in API Inspections Suggest Strategies for Improvement
Recent Videos
Behind the Headlines, Episode 17
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics. ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines. ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.